Recent Company News

• 01:35 AM ET Dec 22, 2025
  

  Chugai Pharmaceutical obtains approval in Japan for Tecentriq for additional indication of thymic carcinoma (¥8262.0000, 0)

• 01:02 AM ET Dec 22, 2025
  

  FDA approves Roche's Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma (CHF 325.50, 0.00)

• 06:49 AM ET Dec 18, 2025
  

  Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial ($1041.79, 0.00)

• 01:09 AM ET Dec 17, 2025
  

  Galderma Group announces new clinical data confirming nemolizumab's rapid onset of action on itch and sleep; data published in the Journal of the European Academy of Dermatology and Venereology (CHF 162.00, 0.00)

• 10:10 PM ET Dec 14, 2025
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (202 total)

• 10:06 PM ET Dec 14, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (101 total)

• 01:09 AM ET Dec 11, 2025
  

  Galderma Group announces first patient enrollment for phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CHF 167.80, 0.00)

• 09:44 PM ET Dec 10, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 08:16 AM ET Dec 10, 2025
  

  Roche's giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer (CHF 313.00, -2.30)

• 04:49 PM ET Dec 08, 2025
  

  Genentech presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas (CHF 317.70, 0.00)